Showing 4461-4470 of 9741 results for "".
- Valeant Announces CEO Succession Plan And Changes To Board; Provides Accounting And Financial Reporting Updatehttps://practicaldermatology.com/news/valeant-announces-ceo-succession-plan-and-changes-to-board-provides-accounting-and-financial-reporting-update/2458640/Valeant’s board has initiated a search to identify a candidate to succeed J. Michael Pearson as chief executive officer (CEO). Mr. Pearson will continue to serve as CEO and a director until his replacement is appointed. The company also announced that William A. Ackman, CEO of Persh
- Revance Therapeutics Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Developmenthttps://practicaldermatology.com/news/revance-therapeutics-appoints-roman-g-rubio-md-mba-as-senior-vice-president-of-clinical-development/2458649/Revance Therapeutics, Inc. has named Roman G. Rubio, MD, MBA Senior Vice President of Clinical Development. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Reva
- Practical Dermatology® Launches #PDGivesBack to Support Camp Discovery at AAD 2016https://practicaldermatology.com/news/practical-dermatology-launches-pdgivesback-to-support-camp-discovery-at-aad-2016/2458672/Bryn Mawr Communications III’s Practical Dermatology® magazine is inviting attendees at the 74th Annual Meeting of the American Academy of Dermatology (AAD) to give back as part of its new “selfless-selfies” campaign.
- Novel Nanotechnology Delivery System May Offer New Approach to Skin Disease Treatmenthttps://practicaldermatology.com/news/novel-nanotechnology-delivery-system-may-offer-new-approach-to-skin-disease-treatment/2458675/A new nanotechnology-based delivery system may help activate the body's natural defense against free radicals and control a variety of skin conditions, report researchers from The Hebrew University of Jerusalem and Technion -- Israel Institute of Technology. Specifically, applyi
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11
- Promius Receives FDA Approval for Sernivo Spray for Psoriasishttps://practicaldermatology.com/news/promius-receives-fda-approval-for-sernivo-spray-for-psoriasis/2458715/Dr. Reddy’s US subsidiary Promius Pharma received FDA approval for Sernivo (betamethasone dipropionate) Spray 0.05%. Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic